Zydus Lifesciences gets USFDA’s tentative nod for Azilsartan Medoxomil and Chlorthalidone Tablets

14 Jun 2024 Evaluate

Zydus Lifesciences has received tentative approval from the United States Food and Drug Administration (USFDA) to market Azilsartan Medoxomil and Chlorthalidone Tablets, 40 mg/12.5 mg and 40 mg/25 mg (USRLD: Edarbyclor tablets).

Azilsartan and chlorthalidone is an angiotensin II receptor blocker (ARB) and a thiazide like diuretic combination product indicated for the treatment of high blood pressure (hypertension), to lower blood pressure. The drug will be manufactured at the group’s formulation manufacturing facility in Ahmedabad SEZ - II, India. Azilsartan Medoxomil and Chlorthalidone Tablets had annual sales of $77.9 million in the United States (IQVIA MAT March 24).

The group now has 397 approvals and has so far filed over 460 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.


Zydus Lifesciences Share Price

917.45 -4.55 (-0.49%)
12-Mar-2026 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1825.00
Dr. Reddys Lab 1320.00
Cipla 1325.25
Zydus Lifesciences 917.45
Lupin 2355.00
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×